ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

INO vs TRDA // NET PROFIT MARGIN

Inovio Pharmaceuticals Inc. (NASDAQ) VS. Entrada Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: INO 1 — TRDA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INO VS. TRDA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC INO TRDA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% -65.00% 0.00 TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 72.7 49.6 +23.10 INO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $195.4M $199.0M -$3.5M TRDA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR INO REV TRDA REV INO GROSS % TRDA GROSS % INO FCF TRDA FCF
FY 2025 $65.3K $25.4M — — -$88.9M -$129.6M
FY 2024 $217.8K $210.8M — — -$104.6M -$44.7M
FY 2023 $832.0K $129.0M — — -$124.4M $139.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INO // BETA —
TRDA // BETA —